Kornimate/medical-research-clean huggingface dataset:
investigation of the efficacies of multi berries juice on anti oxidant effect and improvement of skin conditions

Conditions: Skin Condition; Anti Oxidative Stress

Summary: to assess multi berries juice on anti-oxidant effect and skin condition improvement


Eligibility criteria:
inclusion criteria: * healthy adults aged above 20 years old exclusion criteria: * subject who is not willing to participate in this study. * patients with diseases of the skin, liver, kidney. * subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder. * female who is pregnant or nursing or planning to become pregnant during the course of the study. * received facial laser therapy, chemical peeling or uv overexposure in the past 4 weeks. * constant drug use
efficacy and safety of lenvatinib as a conversion therapy for hcc

Conditions: Hepatocellular Carcinoma (HCC)

Summary: lenvatinib is the standard of care for patients with advanced hepatocellular carcinoma (hcc). the aim of the single-arm, open-label, phase ii clinical trial is to assess efficacy and safety of lenvatinib as a preoperative conversion therapy in patients with potentially resectable hcc. investigator hypothesized that lenvatinib may be an effective conversion treatment for hcc, and preoperative treatment with lenvatinib can improve resectability in patients with potential resectable hcc and improve the long term survival.

for patients with potentially resectable hcc (intermediate or advanced stage), upfront therapy with surgical resection is of high recurrence rate after surgery. the aim of the single-arm, open-label, prospective phase ii clinical trial is to evaluate whether preoperative lenvatinib treatment could improve resectability and therefore improve the long term survival. participants who are recruited in this study in this study will be treated with lenvatinib and will be evaluated for the feasibility for surgical resection by a multidisciplinary team every 8 weeks. if the participants underwent curative resection, they will receive lenvatinib treatment for 48 weeks after surgery.

Eligibility criteria:
inclusion criteria: 1. male or female aged 18-75; 2. the participant must have confirmed diagnosis of hcc histologically or clinically; 3. the participant must have at least one untreated intrahepatic lesion that can be evaluated by contrast-enhanced ct or mri; 4. the bclc stage b/c patients, more than 3 tumor nodes or have portal vein tumor thrombus (vp3-vp4 according to lcsgj pvtt classification) or extrahepatic metastases limited to one organ and the number of metastases nodules is no more than 3; 5. ecog ps 0-1 and child-pugh a; 6. surgical resection is not the first choice according to mdt evaluation; 7. written informed consent; exclusion criteria: 1. wbc\<4.0\*10\^9/l, hb\<80 g/l, plt\<75\*10\^9/l and neut\<1.5×10\^9/l; 2. coagulation function: (prothrombin time) international normalized ratio (inr) \>1.2; 3. liver function: serum albumin (alb)\ 1.5 times the upper limit of normal range, alanine aminotransferase and aspartate aminotransferase (alt and ast)\>3 times the upper limit of normal range; renal function index: serum creatinine (cre)\>1.5 times the upper limit of normal range; uncontrolled hypertension (\>150/90mm hg); 4. lymph node metastasis to hilar of lung or liver, or peripheral tissue adhesion; 5. participated in other clinical trials 30 days before enrollment; 6. with ascites, hepatic encephalopathy, gilbert syndrome, sclerosing cholangitis; 7. suspected allergy to study drug; 8. with other organ dysfunction, it is not expected to be tolerated general anesthesia or hepatectomy; 9. other conditions that the investigators considered not unsuitable for inclusion.
a study of letermovir (mk-8228) to evaluate efficacy and safety for prevention of cytomegalovirus infection in chinese hematopoietic stem cell transplant recipients (mk-8228-045)

Conditions: Cytomegalovirus Infection

Summary: the purpose of this study is to evaluate the efficacy and safety of a once-a-day oral or intravenous (iv) dose of letermovir (mk-8228) in chinese adult hematopoietic stem cell transplant (hsct) recipients for the prevention of clinically significant cytomegalovirus (cmv) infection.


Eligibility criteria:
the key inclusion and exclusion criteria include but are not limited to the following: inclusion criteria: * male/female chinese adult participant of an allogeneic hematopoietic stem cell transplant (hsct). * has documented positive cytomegalovirus (cmv) serostatus (cmv immunoglobulin g \[igg\] seropositive) for recipient (r+) at the time of screening. * is receiving a first allogeneic hsct. * is within 28 days post-hsct at the time of randomization. * female participant is not a woman of child bearing potential (wocbp) or is a wobcp who agrees to use acceptable contraception during the treatment period and for ≥28 days after the last dose of study drug. exclusion criteria: * received a previous allogeneic hsct. * has a history of cmv end-organ disease within 6 months prior to randomization. * has evidence of cmv viremia at any time from hsct procedure until the time of randomization. * has severe hepatic insufficiency. * is a) on renal replacement therapy (e.g., hemodialysis, peritoneal dialysis) or b) has end stage renal impairment with a creatinine clearance \<=10 ml/min within 5 days prior to randomization. * has both moderate hepatic insufficiency and moderate to severe renal insufficiency. * has an uncontrolled infection on the day of randomization. * has rapidly progressing disease that requires mechanical ventilation or is hemodynamically unstable. * has a documented positive result for a human immunodeficiency virus antibody (hiv-ab) test at any time prior to randomization, or for hepatitis c virus antibody (hcv-ab) with detectable hcv ribonucleic acid (rna), or hepatitis b surface antigen (hbsag) within 90 days prior to randomization. * has active solid tumor malignancies except localized basal cell or squamous cell skin cancer or the condition under treatment (e.g., lymphomas). * has received any prohibited medications within 2 days prior to initiation of treatment with letermovir. * is anticipated to be treated with traditional chinese medicine or herbal medicine during the study treatment period and for 14 days after study medication.
effectiveness and safety of the nursing prescription in acute health problems of low complexity

Conditions: Acute Disease

Summary: objective: to compare the efficacy/effectiveness of pharmacological nurse prescription with medical prescription in patients attended in a primary care center for minor acute health problems. scope of the study: multicenter study, with the participation of 8 primary care centers of catalonia. methodology: randomized blind clinical trial, with experimental group receiving pharmacological nurse prescription and a control group receiving medical prescription. subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria, with random assignment of 374 subjects, 187 per group. the efficacy/effectiveness of the prescribed treatment will be considered as a no re-attendance during the following 72h and will be completed with the variables: information and knowledge of the treatment, adverse effects, compliance, satisfaction level and resolution of the health problem. the data collection is done 10 days after the visit by an ad-hoc telephone questionnaire of 11 items, previously tested. the analysis is done using the spss software version 21.0, obtaining data of descriptive, multivariate and inferential statistics. implications for practice: to evidence the equivalence of pharmacological nurse prescription with medical prescription for minor acute health problems


Eligibility criteria:
inclusion criteria: * contusion * diarrhea / vomit * fever without focality * flu * urinary distress * odinophagy * toothache * skin bite * upper respiratory symptoms * ankle twist exclusion criteria: * language barrier * cognitive deterioration * sensory deficit * pregnancy * immunosuppression * neoplasia in the last 5 years * does not participate / does not sign consent * breastfeeding period * reconsult * resides outside of spain * treatment with glucocorticoids in the last 6 months

Keywords: prescriptions nurses primary health care acute disease
m-2018-334 in hematological malignancies

Conditions: Hematological Malignancies

Summary: this is a single-center, open-label, single-arm, pilot clinical study using tcrα/β and cd45ra depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation in 12 to 18 adult patients.


Eligibility criteria:
inclusion criteria: * patients, between 18 years to 75 years of age, with high-risk hematological malignancy requiring an allogeneic hematopoietic stem cell transplantation (allohct), but do not have an hla-matched donor available exclusion criteria: * \<3 months after preceding autologous transplantation or prior allohct * history of neurological impairment (active seizures, severe peripheral neuropathy, signs of leukoencephalopathy, active cns infection) * active fungal infections with radiological and clinical progression * liver function abnormalities with bilirubin \>2 mg/dl and elevation of transaminases higher than 400 u/l * chronic active viral hepatitis * cardiac dysfunction: adult patients ejection fraction \<50% on echocardiography * patients with uncontrolled, \>grade ii hypertension (per common toxicity criteria, ctc) * creatinine clearance \<60 ml/min/1.73m2 * respiratory failure necessitating supplemental oxygen * hiv infection * positive anti-donor hla antibody * treatment with checkpoint inhibitors in the period between 3 months prior to and 3 months after transplantation * female patients who are pregnant or breast feeding, or adults of reproductive potential not willing to use an effective method of birth control during study treatment and for at least 12 months thereafter. note: women of childbearing potential must have a negative serum pregnancy test at study entry * concurrent severe or uncontrolled medical disease (e.g., uncontrolled diabetes, myocardial infarction within 6 months prior to the study) which by assessment of the treating physician could compromise participation in the study * patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction). * patients unwilling or unable to comply with the protocol or unable to give informed consent * treatment with any investigational product within 4 weeks prior to study treatment
topical henna preparation for the treatment of hand foot skin syndrome

Conditions: Hand Foot Skin Syndrome

Summary: the purpose of this study is to determine whether henna paste is effective in the treatment of hand-foot skin syndrome, induced by the drugs capecitabine and pegylated liposomal doxorubicin.


Eligibility criteria:
inclusion criteria: * patients receiving capecitabine and/or pegylated liposomal doxorubicin as monotherapy or in combination with other agents * new diagnosis of active hand-foot skin reaction (on bilateral hands and/or bilateral feet) of 1-3 toxicity as defined by the nci-ctcae version 4.0 grading scale with onset of symptoms within the last thirty days * patients must be 18 years or older * patients must provide written informed consent to participate in the study exclusion criteria: * patients with pre-existing dermatological condition affecting the hands or feet that may limit the interpretation of results * known allergy to natural henna * patients with a previous history of hfs * history of g6pd deficiency as determined by screening bloodwork

Keywords: hand foot skin syndrome palmar plantar erythrodysesthesia doxorubicin capecitabine
youth and sport study

Conditions: Physical Activity; Obesity; Lifestyle

Summary: the youth and sport study (yss) is a 20-22-year follow-up study of danish teenagers born between 1964 and 1969. baseline data originate from two different studies carried out in 1983 and 1985, and the follow-up study was carried out in 2005.

the first baseline study was conducted in 1983 and included 1260 students in high school or trade school. the questionnaire was designed with focus on various aspects of sports and physical activity beside more general questions on family, socioeconomic status, height, weight, alcohol intake, smoking, etc. furthermore, the participants were subjected to a set of physical tests and measurements. the second baseline study was conducted in 1985 and included a representative sample of 2498 teenagers drawn from the danish civil registration (cpr) and invited to participate in the study with the aim of validating the results from the first baseline sample. the study consisted of a questionnaire with virtually the same questions as the questionnaire from 1983. a short 28-item food frequency questionnaire (ffq) was added to the questionnaire, as well as a few questions about dietary habits. the follow-up study was carried out in 2005, when the subjects had reached an age of around 40 years. a total of 1904 subjects were traced and asked to complete a general questionnaire, a food frequency questionnaire, and deliver a dna sample, all distributed and returned through mail correspondence. the general questionnaire included questions on education, occupation, height, previous and present weight, weight loss history, physical activity, smoking, civil status, children, other family, stress, diseases, hospital admissions, and medicine use, among other things. the questions about physical activity were adopted from the baseline questionnaire. other questions were adopted from other validated questionnaires. moreover, a semi-quantitative, 195-item food frequency questionnaire (ffq), which previously has been used and validated in the danish "diet, cancer and health" study was included. the study was approved by the local ethics committee for copenhagen and frederiksberg (j.nr. kf 01-260/04).

Eligibility criteria:
danish teenagers born between 1964 and 1969.

Keywords: physical activity obesity overweight lifestyle diet
development of a fall prevention and fall detection system for ambulatory rehabilitation of parkinson's patients

Conditions: Parkinson's Disease

Summary: the investigators plan to conduct a first-stage experiment by recruiting ten subjects, including five pd patients and five non-pd patients. in the beginning, the information collected by the portable motion detector is used to compare the difference in the activities performed by pd and non-pd patients. besides, the algorithm will be developed to identify the gait patterns of pd patients. once the system detects the abnormal gaits, such as shuffling and festinating steps or freezing of gait, auditory cues will be given to the pd patients and caregivers by their sides. it can help the patient to maintain normal gait and improve the effectiveness of rehabilitation, as well as preventing falls in daily activities. moreover, in case of accident falls, the real-time fall detection mechanism alerts the nearest caregiver for instant support and delivers this information to the remote family members and medical personnel. after that, a second-stage experiment will be carried out by recruiting another five pd patients. by comparing the gait patterns identified by the system against those identified manually by the staff, the performance of the proposed system on fall prevention will be examined. for the patients and their family members, the developed system enhances the patients' safety in their daily activities. as for the medical personnel, it serves as an affordable tool that benefits the rehabilitation of pd patients in an easy manner.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson's disease exclusion criteria: * cardiac disease * mobility disability
study to compare the safety and pharmacokinetic characteristics of lbec0101 25 mg with those of enbrel®

Conditions: Healthy

Summary: to compare the pharmacokinetic characteristic of lbec0101 25mg with the active comparator, enbrel® 25 mg.


Eligibility criteria:
inclusion criteria: * healthy males, 20 to 45 years of age the moment of screening * body mass index is between 18.0 and 30.0 kg/m exclusion criteria: * the tuberculosis patient or latent tuberculosis patient * hypersensitivity response to the test and comparator drugs

Keywords: etanercept enbrel healthy volunteers
bromocriptine and pentoxifylline in ophthalmopathy autoimmune treatment

Conditions: Graves Ophthalmopathy

Summary: autoimmune ophthalmopathy is clinically evident in one third of graves' disease cases. in most cases it is mild; however, in 3 to 5% of cases it has a severe presentation. at present, the treatment is directed to identify vision threatening which requires aggressive intervention, usually with glucocorticoids. for mild cases the treatment is limited to the normalization of hyperthyroidism and support measures. preliminary data show that pentoxifylline and bromocriptine may have a favorable effect in the course of ophthalmopathy by inhibition of the synthesis of tnf-α, vegf, glycosaminoglycan production, and lymphocyte infiltration. therefore, the aims of this study were to evaluate the effect of bromocriptine and pentoxifylline on the clinical course and quality of life of patients with mild to moderate ophthalmopathy associated to graves´disease. methods. patients with mild to moderate ophthalmopathy, with less than one year of evolution, and naive to treatment were randomized to receive treatment during 12 months with either 1) bromocriptine (5 mg twice a day) + methimazole (30 mg/day), 2) pentoxifylline (400 mg twice a day) + methimazole (30 mg/day), or 3) methimazole only (30 mg/day). they completed 10 visits to evaluate proptosis and clinical activity score (cas). in addition, in the first and last visit the quality of life questionnaire specific for graves' ophthalmopathy(go-qol) was applied.


Eligibility criteria:
inclusion criteria: * women or men * between 18 and 45 years * autoimmune hyperthyroidism with one year or less of evolution * no previous treatment * mild to moderate ophthalmopathy exclusion criteria: * smoking * severe ophthalmopathy * steroid treatment * asthma * diabetes or other significant disease * creatine \>1.5 mg/dl * women with child bearing potential not using a birth control method * opthalmologic diseases * uncontrolled hypertension * history of ischemic cardiopathy * history of stroke * history of gastrointestinal bleeding

Keywords: graves ophthalmopathy exophthalmos proptosis quality of life
building lipedema research resources

Conditions: Lipedema

Summary: lipedema is a disease marked by subcutaneous adipose tissue accumulation in the lower extremities of females that is accompanied by somatic pain and edema. importantly, lipedema is commonly misdiagnosed as obesity, although it's estimated to affect a high 11% of women. clinical diagnosis of lipedema requires specialized training not widely available at most major medical centers, and there remains a substantial need for objective tools to distinguish lipedema from obesity. there is a critical need to define specific molecular markers of disease in circulation or at the tissue-level. the purpose of this study is to create, manage, and characterize an innovative lipedema biorepository. the goal of the biorepository will be to better understand disease mechanisms of lipedema and to define specific molecular markers of disease in circulation or at the tissue-level. the long-term purpose of our studies are to help with prevention and early management of lipedema.


Eligibility criteria:
inclusion criteria: * participants with or without lipedema * age range = 18-80 years * participants with lipedema have a formal diagnosis by a physician using criteria in appendix a of protocol * female exclusion criteria: volunteers in the lipedema or control group will be excluded with the following: * pregnant or breast-feeding * taking any anticoagulation or antiplatelet therapy other than aspirin (up to 100 mg daily) * active infection anywhere in the body, or open wound on the lower-extremities or at locations for ultrasound, bioimpedance, and tissue dielectric measurements * battery-operated device implanted that cannot be removed for ultrasound, dxa scan, bioimpedance, and tissue dielectric measurements * primary lymphedema * uncontrolled diabetes, renal disease, thyroid disease, or hypertension * hormone dysregulation or another significant clinical condition affecting hormone status as confirmed by clinical co-investigators * bone metastases * contrast imaging scan in the previous 7 days * nuclear medicine scan in previous 3 days * lumbar spine fusion * weigh more than 500 lb (226.8 kg) also excluded are subjects incapable of giving informed written consent: * subjects who have an inability to communicate with the researcher for any reason * subjects who are non-english speaking who cannot communicate through a translator, or if a translator is not available * subjects who cannot adhere to the experimental protocols for any reason * subjects who have limited mental ability to give informed consent due to mental disability, confusion, or psychiatric disorders * prisoners
phase 2 study of temozolomide in pre-selected advanced aerodigestive tract cancers (study p04273am2)(terminated)

Conditions: Colorectal Neoplasm; Head and Neck Neoplasm; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasm

Summary: this study is proposed to evaluate the efficacy and safety of temozolomide, an oral anti-cancer agent, in a participant population selected for a biomarker. participants with colorectal cancer, non-small-cell lung cancer, head and neck cancer, or esophageal cancer will be included.


Eligibility criteria:
inclusion criteria: * participants must be at least 18 years of age. * participants must have metastatic colorectal cancer (crc), recurrent or metastatic head \& neck (h\&n) or esophageal cancer, or locally advanced, inoperable, or metastatic non-small cell lung cancer (nsclc). * participants must have a tumor sample or a blood sample tested positive for the presence of the biomarker. * participants may have up to 3 prior regimens for crc, up to 3 prior regimens for nsclc, up to 2 prior regimens for h\&n and esophageal cancer. * participants must have at least one measurable lesion. * participants must have an eastern cooperative oncology group (ecog) performance status of 0, 1, or 2. * participants must have adequate hematologic, renal, and liver functions. * participants must be able to take the study medication capsules orally, or through a feeding tube without the capsules being opened. * participants of childbearing potential must agree to use a medically accepted method of contraception. exclusion criteria: * participants who have received treatment for a second malignancy within 1 year before screening, and are considered to be at risk of relapse within 1 year after screening. * participants with unstable or progressing central nervous system (cns) metastasis. participants with known cns metastasis may be included if a) the subject is asymptomatic, b) there is no requirement for steroids or antiseizure medications, or the required doses are stable, and c) there is no associated midline shift or (in the opinion of the investigator) significant edema. * participants who received prior temozolomide or dacarbazine treatment